JP2020516291A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516291A5
JP2020516291A5 JP2019555865A JP2019555865A JP2020516291A5 JP 2020516291 A5 JP2020516291 A5 JP 2020516291A5 JP 2019555865 A JP2019555865 A JP 2019555865A JP 2019555865 A JP2019555865 A JP 2019555865A JP 2020516291 A5 JP2020516291 A5 JP 2020516291A5
Authority
JP
Japan
Prior art keywords
human
glycosylated recombinant
recombinant human
ids precursor
human ids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019555865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027568 external-priority patent/WO2018191666A1/en
Publication of JP2020516291A publication Critical patent/JP2020516291A/ja
Publication of JP2020516291A5 publication Critical patent/JP2020516291A5/ja
Priority to JP2022209169A priority Critical patent/JP2023052096A/ja
Priority to JP2025019080A priority patent/JP2025087702A/ja
Pending legal-status Critical Current

Links

Images

JP2019555865A 2017-04-14 2018-04-13 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療 Pending JP2020516291A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209169A JP2023052096A (ja) 2017-04-14 2022-12-27 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
JP2025019080A JP2025087702A (ja) 2017-04-14 2025-02-07 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762485659P 2017-04-14 2017-04-14
US62/485,659 2017-04-14
US201762573921P 2017-10-18 2017-10-18
US62/573,921 2017-10-18
US201762574355P 2017-10-19 2017-10-19
US62/574,355 2017-10-19
US201762579686P 2017-10-31 2017-10-31
US62/579,686 2017-10-31
PCT/US2018/027568 WO2018191666A1 (en) 2017-04-14 2018-04-13 Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209169A Division JP2023052096A (ja) 2017-04-14 2022-12-27 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療

Publications (2)

Publication Number Publication Date
JP2020516291A JP2020516291A (ja) 2020-06-11
JP2020516291A5 true JP2020516291A5 (https=) 2021-05-27

Family

ID=63793615

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555865A Pending JP2020516291A (ja) 2017-04-14 2018-04-13 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
JP2022209169A Pending JP2023052096A (ja) 2017-04-14 2022-12-27 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
JP2025019080A Pending JP2025087702A (ja) 2017-04-14 2025-02-07 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209169A Pending JP2023052096A (ja) 2017-04-14 2022-12-27 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
JP2025019080A Pending JP2025087702A (ja) 2017-04-14 2025-02-07 ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療

Country Status (12)

Country Link
US (2) US11613739B2 (https=)
EP (1) EP3609526A4 (https=)
JP (3) JP2020516291A (https=)
KR (2) KR20190139951A (https=)
AU (2) AU2018253303B2 (https=)
BR (1) BR112019021569A2 (https=)
CA (1) CA3059441A1 (https=)
IL (2) IL269892B2 (https=)
SG (1) SG11201909361SA (https=)
TW (2) TW202532642A (https=)
UY (1) UY37679A (https=)
WO (1) WO2018191666A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
CN110960671A (zh) * 2019-12-25 2020-04-07 广州中医药大学(广州中医药研究院) Elabela多肽新用途及其药物
BR112022015183A2 (pt) * 2020-01-29 2022-12-20 Regenxbio Inc Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
EP4291249A2 (en) * 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
GB2437893A (en) * 2006-07-25 2007-11-07 Celladon Corp Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
ES2635726T3 (es) * 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
CN115120746A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
DK3107562T3 (da) * 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP3166626B1 (en) 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US20180185495A1 (en) * 2014-11-10 2018-07-05 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
WO2016126729A1 (en) 2015-02-03 2016-08-11 Visa International Service Association Validation identity tokens for transactions
HK1256341A1 (zh) 2015-05-15 2019-09-20 明尼苏达大学董事会 用於治疗性递送到中枢神经系统的腺相关物
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
IL258005B2 (en) * 2015-09-17 2025-01-01 Res Inst Nationwide Childrens Hospital Methods and materials for gene therapy for beta-4,1-N-acetylgalactosaminyltransferase 2
SG10201912761UA (en) 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
BR112022015183A2 (pt) 2020-01-29 2022-12-20 Regenxbio Inc Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)

Similar Documents

Publication Publication Date Title
JP2020516291A5 (https=)
Ekström et al. Saliva and the control of its secretion
IL276464B1 (en) Methods and compositions for administering therapeutic protein
JP2023070682A5 (https=)
JP2019506141A5 (https=)
JP2010195794A (ja) Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
DE60041265D1 (de) Verwendung eines polypeptids zur auffindung von multipler sklerose
JP2020508289A5 (https=)
KR20180102172A (ko) 다논병 및 다른 자가포식 장애의 치료 방법
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
JP6949867B2 (ja) 神経の過剰興奮を治療するための方法および組成物
KR102074336B1 (ko) 뇌유래-신경영양인자를 발현하는 중간엽줄기세포주 및 이의 용도
JP2023512242A5 (https=)
WO2024173835A3 (en) Methods and compositions for administering otoferlin dual vector systems
KR102811229B1 (ko) 재조합 핵산 구조물
JP2022529500A (ja) ９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用
CN111936622B (zh) 重组痘苗病毒和包含其的药物组合物
JP2004537284A5 (https=)
US20220233653A1 (en) Camkk1 as a novel regenerative therapeutic
WO2022219333A1 (en) Signal peptides
CA3200660A1 (en) Sonogenic stimulation of cells expressing bacterially-derived mechanosensitive proteins
US20220333107A1 (en) Vasculogenic fibroblasts
WO2008118100A1 (en) Method of enhancing migration of neural precursor cells
HUP0103994A2 (hu) Eljárás proszapozin receptor-aktivitásának serkentésére
CN116847873A (zh) 脑损伤治疗